Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: Negative association between levels of pro‐inflammatory cytokines and development of B19‐associated arthritis
- 13 July 2004
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 74 (1) , 147-155
- https://doi.org/10.1002/jmv.20158
Abstract
The aim of the study was to characterise the profile and clinical correlates (arthritis, rash, and fatigue) of cytokines, chemokines, and other mediators in symptomatic acute parvovirus B19 infection. Serum was examined from cases of acute B19 infection (as defined by serum anti-B19 IgM positivity) (n = 84), and in normal persons (n = 43) for B19 markers (serum B19 antibodies and DNA), rheumatoid factor (RF), and antinuclear antibody (ANA). A panel of cytokines/chemokines was measured in duplicate using the Bioplex Protein Array system (BioRad Hemel Hempstead, UK). These included interleukin-1β (IL-1β), IL-4, IL-5, IL-6, IL-8, IL-13, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), macrophage chemoattractant protein-1 (MCP-1), granulocyte-monocyte colony stimulating factor (GM-CSF), transforming growth factor-β1 (TGF-β1), endothelin-1 (ET-1), and neopterin. Acute symptomatic infection was characterised by specific IgG positivity (83%), serum B19 DNA positivity (96%), and raised levels of IL-4, IL-6, IL-8, TNF-α, IFN-γ, MCP-1, GM-CSF, TGF-β1, and ET-1. Patients with acute B19-associated arthritis were found to have lower levels of IL-6, TNF-α, and GM-CSF than patients without arthritis, while those with rash had lower levels of TGF-β1. It is concluded that cytokine levels following acute symptomatic infection with parvovirus B19 indicate a state of immune activation. The profile of circulating mediators may provide insights into the possible pathogenesis of particular clinical manifestations of this infection. J. Med. Virol. 74:147–155, 2004.Keywords
This publication has 35 references indexed in Scilit:
- Points of control in inflammationNature, 2002
- Parvovirus B19 infection of cultured skin fibroblasts from systemic sclerosis patients: Comment on the article by Ray et alArthritis & Rheumatism, 2002
- Transforming Growth Factor-beta1 Gene Polymorphism and Bone Mineral DensityPublished by American Medical Association (AMA) ,2001
- Human Parvovirus B19 Infection in Infancy Associated with Acute and Chronic Lymphocytic Myocarditis and High Cytokine Levels: Report of 3 Cases and ReviewClinical Infectious Diseases, 2000
- Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damageProceedings of the National Academy of Sciences, 2000
- Raynaud's Phenomenon as a Manifestation of Parvovirus B19 Infection: Case Reports and Review of Parvovirus B19 Rheumatic and Vasculitic SyndromesClinical Infectious Diseases, 2000
- Association of a Polymorphism of the Transforming Growth Factor-β1 Gene with Genetic Susceptibility to Osteoporosis in Postmenopausal Japanese WomenJournal of Bone and Mineral Research, 1998
- Viral-associated haemophagocytosis and elevated serum TNF-α with parvovirus-B19-related pancytopenia in patients with hereditary spherocytosisClinical and Laboratory Haematology, 1994
- The human endothelin-1 gene (EDN1) encoding a peptide with potent vasoactive properties maps distal to HLA on chromosome arm 6p in close linkage to D6S89Cytogenetic and Genome Research, 1993
- Experimental Parvoviral Infection in HumansThe Journal of Infectious Diseases, 1985